BRIGHT-4 Trial Summary: Bivalirudin in STEMI
2022 BRIGHT-4 TRIAL Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with STEMI undergoing primary PCI investigator-initiated, open-label, randomized controlled trial Objective: To...
NAPLES III Trial Summary: Bivalirudin in Patients with High Risk of Bleeding Undergoing LHC
2015 NAPLES III TRIAL Randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting double-blind, single-center,...